Latest Regulatory Progress News

Silver Mines Limited advances the Bowdens Silver Project by updating ecological surveys under new biodiversity laws, aiming for a legally robust development application redetermination by mid-2026.

Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.

Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.

Imricor Medical Systems has secured Charité University Hospital in Berlin as the second global site for its VISABL-VT clinical trial, marking a significant milestone in real-time MRI-guided cardiac ablation technology.

Micro-X has raised $6.18 million through a placement that sees strategic partner Billion Prima increase its stake to 8.6%, funding key commercial and manufacturing scale-up initiatives in medical imaging.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.

Renergen Limited and ASP Isotopes Inc. have cleared all conditions for their merger scheme, setting the stage for integration and a production update from the Virginia Gas Project early next year.

Proteomics International has secured a US patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma, marking a critical step toward commercialisation in the world’s largest healthcare market.

Kingsland Minerals has initiated a Pre-feasibility Study for its Leliyn Graphite Project, partnering with Quinbrook to test graphite concentrate for battery anode applications. This marks a significant step toward developing a world-scale graphite operation in the Northern Territory.

Native Mineral Resources reports steady gold production at Blackjack with 1,300 ounces yielded and $7.6 million revenue, while advancing regulatory and joint venture developments.

Jameson Resources has raised an extra A$450,000 through a discounted share placement, reinforcing investor confidence in its Crown Mountain coal project amid ongoing regulatory progress.

Imugene Limited has received positive feedback from the FDA, aligning key requirements to progress its azer-cel therapy into a pivotal clinical trial, underscoring its growing promise in blood cancer treatment.